Orient Technologies (NSE: ORIENTTECH) Q3 FY26 results: Why short-term margin pain may be the price of securing long-cycle government and services revenue
Read More 5 minute read Pharma Industry News Can OrsoBio’s TLC-6740 combination data reopen the race for post-GLP obesity differentiation? OrsoBio’s TLC-6740 combo data hints at a new way to extend GLP-1 weight loss without higher doses. Read what this means for obesity drug development. byPallavi MadhirajuDecember 16, 2025